Your order has been successfully placed! Typically, orders will be delivered within 2-8 business days to the address you provided. If any issues arise with your order request, a CoverOne representative will reach out to you.

Order your Patient Support Kit

The TEPMETKO Patient Support Kit is intended solely for appropriate patients who have been prescribed TEPMETKO® (tepotinib) by their healthcare provider and is provided for educational and informational purposes only. It does not contain TEPMETKO and is not intended to diagnose any disease, side effect, or replace medical advice by your healthcare provider. Always talk to your healthcare provider about your treatment, side effects, side effect management, or any questions or concerns you may have. Treatment experiences may vary.

To receive the TEPMETKO Patient Support Kit (one per patient), please fill out the information below.

ACKNOWLEDGMENT

I authorize EMD Serono, Inc. (EMD Serono), and companies working with or on behalf of EMD Serono, to contact me via email, mail, or phone to conduct marketing activities, which includes, but is not limited to, providing me with educational and promotional materials, information on EMD Serono products and patient support services, special offers, and services related to my therapy or my medical condition, and/or to conduct market research activities, which includes contacting me to participate in focus groups, surveys, or interviews which may be funded or sent by a CoverOne® Support Program or an EMD Serono affiliate. I understand that EMD Serono will not release my personally identifiable information to any party, except as provided in this authorization or as permitted by applicable law, without first obtaining my (or my authorized representative’s) separate written consent. I understand that I may revoke this authorization at any time by contacting EMD Serono and CoverOne at 1-844-826-8371 or in writing at 200 Pier 4 Blvd., Boston, MA 02210.

PATIENT INFORMATION (all fields are required)

*For compression stockings: Calf size refers to the measurement of the widest part of the lower leg, between the knee and ankle. Measure your calf with a tape measure. If you are between sizes, it is advisable to go for the larger size.

You may report side effects to FDA at 1-800-FDA-1088 or at
www.fda.gov/medwatch

If you need assistance, please contact:

Phone: 844-826-8371 I Fax: 800-214-7295 I CoverOne.com
Hours: Monday–Friday, 8:00 AM–8:00 PM Eastern Time

Use and access of this form are subject to the terms and conditions set out in our
Legal Statement and Privacy Policy.

©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
TEPMETKO and CoverOne are registered trademarks of Merck KGaA, Darmstadt, Germany
or its affiliates. US-TEP-00981 05/25

TEPMETKO® (tepotinib) targets cancer-driving MET proteins, so you can focus on what matters

The ONLY approved
ONCE-DAILY oral treatment*

For eligible individuals living with metastatic non-small cell lung cancer (mNSCLC) with MET exon 14 skipping (METex14) alterations†

INDICATION

What is TEPMETKO used for?

TEPMETKO® (tepotinib) is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body (metastatic), and
  • whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your healthcare provider will perform a test to make sure that TEPMETKO is right for you.

It is not known if TEPMETKO is safe and effective in children.

See how TEPMETKO may help

*Recommended dose is 450 mg once daily with food; see TEPMETKO dosing information to learn more.

†METex14 skipping is a biomarker representing specific abnormal changes in the MET gene that may drive cancer growth.

Do you know your MET status?

See TEPMETKO clinical trial results Learn about taking TEPMETKO Get financial and support information

“See me not letting lung cancer define everything about me.”

Learn more about Choosing TEPMETKO
isi-open

Important Safety Information

What Warnings should I know about TEPMETKO?

TEPMETKO may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including: trouble breathing; shortness of breath; cough; or fever.

 

TEPMETKO may cause abnormal liver blood test results. One patient died from liver failure. Your healthcare provider will do blood tests to check your liver function before you start treatment and during treatment with TEPMETKO. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including: your skin or the white part of your eyes turns yellow; dark or “tea colored” urine; light-colored stools (bowel movements); confusion; tiredness; loss of appetite for several days or longer; nausea and vomiting; pain, aching, or tenderness on the right side of your stomach-area (abdomen); weakness; or swelling in your stomach-area.

 

TEPMETKO may cause increases in your blood amylase and lipase levels that may indicate a problem with your pancreas. Your healthcare provider will do blood tests to check your pancreatic function before you start treatment and during treatment with TEPMETKO. Tell your healthcare provider right away if you develop upper stomach (abdominal) pain, weight loss, nausea, or vomiting.

 

TEPMETKO can cause harm to an unborn baby in pregnant women. 

Females who are able to become pregnant: 

  • Your healthcare provider may do a pregnancy test before you start treatment with TEPMETKO.
  • You should use effective birth control (contraception) during treatment and for 1 week after the last dose of TEPMETKO. Talk to your healthcare provider about birth control methods that may be right for you. 

Males with female partners who are able to become pregnant should use effective birth control during treatment with TEPMETKO and for 1 week after the last dose of TEPMETKO. 

 

What should I tell my health care provider? 

Tell your healthcare provider about all of your medical conditions, including if you: 

  • have or have had lung or breathing problems other than your lung cancer 
  • have or have had liver problems
  • have or have had pancreatic problems
  • are pregnant or plan to become pregnant. TEPMETKO can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if TEPMETKO passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of TEPMETKO.

 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

 

What are the side effects of TEPMETKO? 

The most common side effects of TEPMETKO include: swelling in your face or other parts of your body; nausea; tiredness; diarrhea; muscle and joint pain; shortness of breath; loss of appetite; rash; and changes in certain blood tests. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TEPMETKO if you develop serious side effects during treatment. These are not all of the possible side effects of TEPMETKO. Call your doctor for medical advice about side effects. 

 

You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

Indication

What is TEPMETKO used for?

TEPMETKO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that: 

  • has spread to other parts of the body (metastatic), and 
  • whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your healthcare provider will perform a test to make sure that TEPMETKO is right for you. 

It is not known if TEPMETKO is safe and effective in children.

 

Please see full Prescribing Information and Patient Information.

isi-open

Important Safety Information

What Warnings should I know about TEPMETKO?

TEPMETKO may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including: trouble breathing; shortness of breath; cough; or fever.

 

TEPMETKO may cause abnormal liver blood test results. One patient died from liver failure. Your healthcare provider will do blood tests to check your liver function before you start treatment and during treatment with TEPMETKO. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including: your skin or the white part of your eyes turns yellow; dark or “tea colored” urine; light-colored stools (bowel movements); confusion; tiredness; loss of appetite for several days or longer; nausea and vomiting; pain, aching, or tenderness on the right side of your stomach-area (abdomen); weakness; or swelling in your stomach-area.

 

TEPMETKO may cause increases in your blood amylase and lipase levels that may indicate a problem with your pancreas. Your healthcare provider will do blood tests to check your pancreatic function before you start treatment and during treatment with TEPMETKO. Tell your healthcare provider right away if you develop upper stomach (abdominal) pain, weight loss, nausea, or vomiting.

 

TEPMETKO can cause harm to an unborn baby in pregnant women. 

Females who are able to become pregnant: 

  • Your healthcare provider may do a pregnancy test before you start treatment with TEPMETKO.
  • You should use effective birth control (contraception) during treatment and for 1 week after the last dose of TEPMETKO. Talk to your healthcare provider about birth control methods that may be right for you. 

Males with female partners who are able to become pregnant should use effective birth control during treatment with TEPMETKO and for 1 week after the last dose of TEPMETKO. 

 

What should I tell my health care provider? 

Tell your healthcare provider about all of your medical conditions, including if you: 

  • have or have had lung or breathing problems other than your lung cancer 
  • have or have had liver problems
  • have or have had pancreatic problems
  • are pregnant or plan to become pregnant. TEPMETKO can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if TEPMETKO passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of TEPMETKO.

 

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

 

What are the side effects of TEPMETKO? 

The most common side effects of TEPMETKO include: swelling in your face or other parts of your body; nausea; tiredness; diarrhea; muscle and joint pain; shortness of breath; loss of appetite; rash; and changes in certain blood tests. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TEPMETKO if you develop serious side effects during treatment. These are not all of the possible side effects of TEPMETKO. Call your doctor for medical advice about side effects. 

 

You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

Indication

What is TEPMETKO used for?

TEPMETKO is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that: 

  • has spread to other parts of the body (metastatic), and 
  • whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your healthcare provider will perform a test to make sure that TEPMETKO is right for you. 

It is not known if TEPMETKO is safe and effective in children.

 

Please see full Prescribing Information and Patient Information.

US-TEP-01030

Last update 05/2025

© 2024 Merck KGaA, Darmstadt, Germany or affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

TEPMETKO and CoverOne are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.

 

Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

 

This site contains information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy. This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada.

Cookie Settings